ANTI-PAR-3 ANTIBODY CLONE 8E8 (C005B-450217)

Specificity

Clone 9B-1 is a rat monoclonal antibody that detects C-C chemokine receptor type 9 (CCR9). It targets an epitope within 25 amino acids from the N-terminal region.

Immunogen

KLH-conjugated linear peptide corresponding to 25 amino acids from the N-terminal region of mouse C-C chemokine receptor type 9 (CCR9).

Application

Quality Control Testing

Evaluated by Flow Cytometry in L1.2 cells transfected with mouse CCR9.

Flow Cytometry Analysis: A 1:500 dilution of this antibody detected CCR9 in one million L1.2 cells transfected with mouse CCR9.

Tested Applications

Immunohistochemistry Applications: A representative lot detected CCR9 in Immunohistochemistry applications (Rivera-Nieves, J., et al. (2006). Gastroenterology. 131(5):1518-29).

Flow Cytometry Analysis: A representative lot detected CCR9 in Flow Cytometry applications (Rivera-Nieves, J., et al. (2006). Gastroenterology. 131(5):1518-29).

Neutralizing: A representative lot specifically neutralized CCR9 function in L1.2 cells overexpressing CCR9. (Rivera-Nieves, J., et al. (2006). Gastroenterology. 131(5):1518-29).

Inhibition: A representative lot inhibited CCL25-induced calcium mobilization in L1.2-CCR9 cells. (Rivera-Nieves, J., et al. (2006). Gastroenterology. 131(5):1518-29).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Target description

C-C chemokine receptor type 9 (UniProt: Q9WUT7; also known as C-C CKR-9, CC-CKR-9, CCR-9, Chemokine C-C receptor 10, CDw199) is encoded by the Ccr9 (also known as Cmkbr10) gene (Gene ID: 12769) in murine species. CCR9 is a multi-pass membrane protein of the G-protein coupled receptor 1 family. It has four extracellular domains, seven transmembrane domains, and four cytoplasmic domains and serves as a receptor for chemokine CCL25/TECK. It is highly expressed in the thymus tissue. It is also expressed on all small intestinal T cells and IgA-producing plasma cells (PCs) from the spleen. It is reported to be crucial for the positioning of PCs to the small intestine. Higher expression of CCR9 is observed in newly generated PCs and it is down-regulated once these cells reach their final destination in the intestine. In wild-type mice, a majority of the PCs are shown to locate to the lower half of the villus where CCL25 is also expressed at high levels. CCR9 deficient mice exhibit reduced number of PCs in the intestine and are unable to mount a T cell dependent antigen specific IgA response. CCR9-/- hematopoietic stem cells are deficient in their ability to generate all major thymocyte subsets. Clone 9B-1 is shown to specifically neutralize CCR9 function and inhibits CCL25-induced calcium mobilization in L.1.2 cells. (Ref.: Svensson, M., et al. (2008). J. Leukoc. Biol. 83(1); 156-164; Rivera-Nieves, J., et al. (2006). Gastroenterology. 131(5); 1518-1529; Pabst, O., et al. (2004). J. Exp. Med. 199(3); 411-416).

Physical form

Purified rat monoclonal antibody IgG2a in PBS without azide.

Reconstitution

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.